Christine Mikail Cvijic net worth and biography

Christine Cvijic Biography and Net Worth

CFO of Neurogene

Christine Mikail, J.D., is President and Chief Financial Officer of Neurogene and serves on the company’s Board of Directors. In her role, Ms. Mikail leads Corporate Strategy and Business Development, Portfolio Management, Operations, and Finance. Ms. Mikail, who joined Neurogene in 2019, brings over two decades of experience supporting biotechnology and pharmaceutical companies in corporate strategy and business development, operations, legal and finance capacities. Prior to Neurogene, Ms. Mikail was Chief Administrative Officer and Head of External Business Development/Alliance Management and General Counsel at Axovant Sciences, Inc., where she was an integral member of the team that raised $362 million in the company’s IPO. Prior to joining Axovant, she held a variety of senior executive positions at NPS Pharmaceuticals, Inc., Dendreon Corporation, Eli Lilly and Company, and ImClone Systems. Ms. Mikail developed her life sciences focus as a corporate and securities lawyer at Reed Smith and WilmerHale. Ms. Mikail graduated cum laude with a B.A. from Rutgers University and earned her J.D. from Fordham University School of Law in New York.

What is Christine Mikail Cvijic's net worth?: The estimated net worth of Christine Mikail Cvijic is at least $2.85 million as of March 13th, 2026. Cvijic owns 105,798 shares of Neurogene stock worth more than $2,848,611 as of April 24th. This net worth approximation does not reflect any other assets that Cvijic may own. Learn More about Christine Mikail Cvijic's net worth.
How do I contact Christine Mikail Cvijic?: The corporate mailing address for Cvijic and other Neurogene executives is 535 W 24th Street, 5th Floor, New York, NY 10011, United States. Neurogene can also be reached via phone at (877) 237-5020 and via email at [email protected]. Learn More on Christine Mikail Cvijic's contact information.
Has Christine Mikail Cvijic been buying or selling shares of Neurogene?: Christine Mikail Cvijic has not been actively trading shares of Neurogene in the last ninety days. Most recently, Christine Mikail Cvijic sold 4,045 shares of the business's stock in a transaction on Friday, March 13th. The shares were sold at an average price of $20.81, for a transaction totalling $84,176.45. Following the completion of the sale, the chief financial officer now directly owns 105,798 shares of the company's stock, valued at $2,201,656.38. Learn More on Christine Mikail Cvijic's trading history.
Who are Neurogene's active insiders?: Neurogene's insider roster includes Stuart Cobb (Chief Scientific Officer), Christine Cvijic (CFO), and Rachel McMinn (CEO). Learn More on Neurogene's active insiders.
Are insiders buying or selling shares of Neurogene?: In the last year, insiders at the sold shares 3 times. They sold a total of 17,639 shares worth more than $328,596.57. The most recent insider tranaction occured on March, 13th when insider Stuart Cobb sold 6,797 shares worth more than $141,445.57. Insiders at Neurogene own 11.6% of the company. Learn More about insider trades at Neurogene.
Information on this page was last updated on 3/13/2026.

Christine Mikail Cvijic Insider Trading History at Neurogene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2026	Sell	4,045	$20.81	$84,176.45	105,798
3/13/2025	Sell	4,501	$16.94	$76,246.94	72,343
11/22/2024	Buy	24,000	$20.48	$491,520.00	76,844

Christine Mikail Cvijic Buying and Selling Activity at Neurogene

Neurogene Company Overview

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Today's Range

Now: $26.93

$26.37

$27.56

50 Day Range

MA: $21.37

$17.21

$27.85

2 Week Range

Now: $26.93

$11.77

$37.27

Volume

233,461 shs

Average Volume

167,183 shs

Market Capitalization

$420.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56